Yves Gillet

Axoltis Pharma is developing NX210c, a groundbreaking treatment for Amyotrophic Lateral Sclerosis (ALS, also known as maladie de Charcot in French), the most frequent of the rare diseases and one of the most devastating. ALS progressively destroys motor neurons, leading to muscle weakness, paralysis, and ultimately death, with very limited treatment options today. NX210c is the first targeted - and most advanced - treatment addressing this high unmet medical need. This peptide restores the blood-brain barrier (BBB), a key factor in ALS, Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. With 7 patents and orphan drug designation in the USA and EU for ALS, NX210c has shown an excellent tolerability profile and is currently being evaluated in a Phase 2 clinical trial on 80 patients, with topline results expected in April 2026. Axoltis, nominated for the prestigious Prix Galien, is a pioneer in BBB restoration and is accelerating the development of NX210c, bringing new hope to millions of patients facing neurodegenerative diseases.

Oria Bioscience is a pioneering French TechBio company expert in generating organelles. We deliver high-quality, intact living organelles, surrounded by their therapeutic membrane targets. For the first time, organelles are being distributed globally and are fully compatible with high-throughput screening campaigns and drug development efforts. Thanks to our microfluidics technology, we supply pharmaceutical laboratories and CROs with purified organelles (lysosomes, mitochondria, and endoplasmic reticulum). Working directly with organelles improves efficacy results, reduces attrition rates in clinical phases, accelerates Hit-to-Lead and Lead Optimization phases, and minimizes your carbon footprint by reducing resources used. Oria’s team brings together over 50 years of expertise in organelles and microfluidics, dedicated to delivering organelles worldwide to meet drug discovery needs. We are making organelles as accessible as cells, driving innovation across all health sectors.

inHEART is committed to delivering the world’s most sophisticated, AI-enabled, digital twin of the heart to advance the care of patients living with cardiac disease. We believe all patients deserve access to world-class expertise that guides and optimizes treatment strategies to support improved clinical outcomes and return patients to full, healthy lives.

Avatar Medical democratizes access to medical images. Our simple, real-time and scalable XR visualization solution seamlessly provides 3D avatars from patient medical images. Whether in consultations, radiology conferences, or the operating room, our real-time technology empowers surgeons with precise and dynamic insights exactly when and where they need them. The company was founded in 2020 by an experienced team of French and American co-founders after four years of extensive research at Institut Pasteur and Institut Curie. It has been marked by multiple prestigious awards, including recognition from EIC accelerator, Sifted, Laval Virtual, Medfit, and Nvidia Inception. Avatar Medical Software has FDA clearance and is under process for CE marking. Avatar Medical Software is FDA-cleared, with CE marking in progress.

Ensemble, construisons un monde qui réemploi ! Devenez actionnaire de Pandobac sur Sowefund : https://sowefund.com/investir/pandobac. Aujourd’hui en France, 3 000 000 emballages alimentaires sont jetés chaque jour. Ces emballages coûtent cher et encombrent les entrepôts, les commerces et poubelles. Remplacer les cartons, les cagettes en bois et le polystyrène par des bacs de transport réutilisables permet de faire des économies, de gagner de l’espace de stockage et de répondre à une demande croissante des restaurateurs et particuliers pour des circuits logistiques plus écologiques. Expert du réemploi, Pandobac vous accompagne sur tous vos projets de passage du jetable au réutilisable. Que vous soyez une entreprise ou une collectivité, que votre projet soit prévu de longue date ou seulement à ses prémices, Pandobac est là pour vous guider sur votre stratégie zéro déchet comme sur la mise en place opérationnelle.

Kard, cest lapp dargent de poche préférée des familles. Une carte et un compte ado pour apprendre la gestion et la valeur de l’argent, une app parent pour tout superviser et les accompagner en toute sécurité. Notre mission : permettre à TOUS les parents d’apprendre l’argent à leurs enfants de façon vraiment adaptée à leurs usages et dans la bonne humeur ! Chez Kard, on y croit dur comme fer : l’argent, ça s’apprend. Lancée en septembre 2019, Kard a levé à date plus de 15 millions deuros auprès de Founders Future et de business angels, dont plusieurs experts mondiaux de la Fintech.

Axoltis Pharma is developing NX210c, a groundbreaking treatment for Amyotrophic Lateral Sclerosis (ALS, also known as maladie de Charcot in French), the most frequent of the rare diseases and one of the most devastating. ALS progressively destroys motor neurons, leading to muscle weakness, paralysis, and ultimately death, with very limited treatment options today. NX210c is the first targeted - and most advanced - treatment addressing this high unmet medical need. This peptide restores the blood-brain barrier (BBB), a key factor in ALS, Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. With 7 patents and orphan drug designation in the USA and EU for ALS, NX210c has shown an excellent tolerability profile and is currently being evaluated in a Phase 2 clinical trial on 80 patients, with topline results expected in April 2026. Axoltis, nominated for the prestigious Prix Galien, is a pioneer in BBB restoration and is accelerating the development of NX210c, bringing new hope to millions of patients facing neurodegenerative diseases.

Oria Bioscience is a pioneering French TechBio company expert in generating organelles. We deliver high-quality, intact living organelles, surrounded by their therapeutic membrane targets. For the first time, organelles are being distributed globally and are fully compatible with high-throughput screening campaigns and drug development efforts. Thanks to our microfluidics technology, we supply pharmaceutical laboratories and CROs with purified organelles (lysosomes, mitochondria, and endoplasmic reticulum). Working directly with organelles improves efficacy results, reduces attrition rates in clinical phases, accelerates Hit-to-Lead and Lead Optimization phases, and minimizes your carbon footprint by reducing resources used. Oria’s team brings together over 50 years of expertise in organelles and microfluidics, dedicated to delivering organelles worldwide to meet drug discovery needs. We are making organelles as accessible as cells, driving innovation across all health sectors.

inHEART is committed to delivering the world’s most sophisticated, AI-enabled, digital twin of the heart to advance the care of patients living with cardiac disease. We believe all patients deserve access to world-class expertise that guides and optimizes treatment strategies to support improved clinical outcomes and return patients to full, healthy lives.

Avatar Medical democratizes access to medical images. Our simple, real-time and scalable XR visualization solution seamlessly provides 3D avatars from patient medical images. Whether in consultations, radiology conferences, or the operating room, our real-time technology empowers surgeons with precise and dynamic insights exactly when and where they need them. The company was founded in 2020 by an experienced team of French and American co-founders after four years of extensive research at Institut Pasteur and Institut Curie. It has been marked by multiple prestigious awards, including recognition from EIC accelerator, Sifted, Laval Virtual, Medfit, and Nvidia Inception. Avatar Medical Software has FDA clearance and is under process for CE marking. Avatar Medical Software is FDA-cleared, with CE marking in progress.

Ensemble, construisons un monde qui réemploi ! Devenez actionnaire de Pandobac sur Sowefund : https://sowefund.com/investir/pandobac. Aujourd’hui en France, 3 000 000 emballages alimentaires sont jetés chaque jour. Ces emballages coûtent cher et encombrent les entrepôts, les commerces et poubelles. Remplacer les cartons, les cagettes en bois et le polystyrène par des bacs de transport réutilisables permet de faire des économies, de gagner de l’espace de stockage et de répondre à une demande croissante des restaurateurs et particuliers pour des circuits logistiques plus écologiques. Expert du réemploi, Pandobac vous accompagne sur tous vos projets de passage du jetable au réutilisable. Que vous soyez une entreprise ou une collectivité, que votre projet soit prévu de longue date ou seulement à ses prémices, Pandobac est là pour vous guider sur votre stratégie zéro déchet comme sur la mise en place opérationnelle.